Comparing and Contrasting Barrier Isolator Decontamination Systems

The contract will support R&D of high-quality APIs for substance use disorders and mental health conditions, starting with synthesis and scale-up of psilocybin, which is derived from mushrooms.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

With financing led by Blue Owl Capital, Latigo will use the funds to further develop non-opioid pain treatments as well as develop other candidates in its pipeline.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Upgraded and dynamic valve platforms as well as advanced sensing will be some of the components of ITT’s exhibit.

The company is highlighting its commitment to next-generation glass manufacturing in efforts to strengthen the pharmaceutical supply chain.